Hörnberg, Hanna
Pérez-Garci, Enrique
Schreiner, Dietmar
Hatstatt-Burklé, Laetitia
Magara, Fulvio
Baudouin, Stephane
Matter, Alex
Nacro, Kassoum http://orcid.org/0000-0002-3291-0215
Pecho-Vrieseling, Eline
Scheiffele, Peter http://orcid.org/0000-0002-9516-9399
Article History
Received: 20 May 2019
Accepted: 25 May 2020
First Online: 5 August 2020
Competing interests
: S.B. P.S. A.M. and K.N. have filed patents on the use of MNK inhibitors for treatment of neurodevelopmental disorders. A.M. and K.N. are current or former employees of the Experimental Drug Development Centre Singapore which has a commercial interest in the development of MNK1/2 inhibitors.